The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • No CSPEC related information was provided by the message!

  • See Evidence submitted by expert panel for details.

Variant: NM_000152.5(GAA):c.2395C>T (p.His799Tyr)

CA8815726

284886 (ClinVar)

Gene: GAA
Condition: glycogen storage disease II
Inheritance Mode: Autosomal recessive inheritance
UUID: fe0e4ece-ff1c-4c30-9e89-69075bb566b9
Approved on: 2023-09-05
Published on: 2023-10-13

HGVS expressions

NM_000152.5:c.2395C>T
NM_000152.5(GAA):c.2395C>T (p.His799Tyr)
NC_000017.11:g.80117663C>T
CM000679.2:g.80117663C>T
NC_000017.10:g.78091462C>T
CM000679.1:g.78091462C>T
NC_000017.9:g.75706057C>T
NG_009822.1:g.21108C>T
ENST00000302262.8:c.2395C>T
ENST00000302262.7:c.2395C>T
ENST00000390015.7:c.2395C>T
ENST00000573556.1:n.348C>T
NM_000152.3:c.2395C>T
NM_001079803.1:c.2395C>T
NM_001079804.1:c.2395C>T
NM_000152.4:c.2395C>T
NM_001079803.2:c.2395C>T
NM_001079804.2:c.2395C>T
NM_001079803.3:c.2395C>T
NM_001079804.3:c.2395C>T

Uncertain Significance

Met criteria codes 4
PM3_Supporting BP4 PM2_Supporting PP4_Moderate

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Lysosomal Diseases VCEP
The NM_000152.5:c.2395C>T variant in GAA is a missense variant predicted to cause substitution of His by Tyr at amino acid 799 (p.His799Tyr). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00038 (6/15954 alleles) in the African population, which is lower than the ClinGen LD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.443 which is below the threshold of 0.5, evidence that does not predict a damaging effect on GAA function (BP4). It only has been reported in one case as LOPD, in which has unknown phase concurrence in compound heterozygous with c.-32-13T>G (PMID: 22958975). Thus met PM3_supporting. The LOPD case has been reported to have GAA residue level 0.25 (normal cutoff unknown. But average of 20 LOPD patients is 8.35, so <10% of normal mean control level). Thus PP4_moderate is applied. There is a ClinVar entry for this variant (Variation ID: 284886, 2 star review status) with 8 submitters classifying the variant as Uncertain significance with no conflicts. In summary, this variant meets the criteria to be classified as Uncertain significance for Pompe disease based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert panel (Specifications Version 2.0): PM2_supporting, PP4_moderate, PM3_supporting, BP4. (Classification approved by the ClinGen Lysosomal Diseases VCEP, September 5, 2023)
Met criteria codes
PM3_Supporting
LOPD patient #1 (PMID: 22958975) has this variant in compound het with c.-32-13T>G. phase unknown. 0.5 points. Thus met PM3_Supporting.
BP4
The computational predictor REVEL gives a score of 0.443 which is below the threshold of 0.5, evidence that does not predict a damaging effect on GAA function (BP4).
PM2_Supporting
The highest population minor allele frequency in gnomAD v2.1.1 is 0.00038 (6/15954 alleles) in the African population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting).
PP4_Moderate
LOPD patient #1 (PMID: 22958975) has LGMD like Clinical aspects. GAA residue level 0.25 (normal cutoff unknown. But average of 20 LOPD patients is 8.35). MWG score=3. % FVC 70%. 2 points. Thus met PP4_Moderate.
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.